KBI Biopharma Holds Ribbon Cutting for New Commercial Manufacturing Facility
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, held a ribbon-cutting at the company’s new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina. The location provides access to highly specialized talent and second-to-none technical and academic training.
Now fully operational, the site employs more than 200 people in production, supply chain, engineering, quality control, and quality assurance positions. That number is expected to grow to 350 by the end of the year, with the site’s intense focus on attracting and hiring high-performing employees. The ribbon-cutting, held on April 20th, was attended by the following:
- Tim Lowery, President, JSR Life Sciences
- Michael Landau, KBI, Interim Chief Operating Officer
- Jesse Kingg, KBI, Senior Vice President & Site Head, Patriot Park
- Laura Rowley, Ph.D., NC Biotech VP, Life Science Economic Development
- Geoff Durham, Durham Chamber President & CEO
KBI built this facility to support the manufacturing of mammalian-based products, starting with an undisclosed client’s late-phase clinical and commercial programs.
“Our new facility allows KBI to remain on the cutting-edge of the latest innovations in automation and digitalization,” said Kingg. “With the highest quality people, systems, and processes, we intend to be a true center of excellence and an exceptional place to work.”
In line with JSR Life Sciences’ ONEDigital initiative, the new facility will incorporate Manufacturing 4.0 principles through the design and integration of advanced technologies. Innovations include:
- Digital data collection systems, including electronic batch records, electronic logbooks, paperless materials management, and Laboratory Information Management Systems (LIMS) for quality control data management. These tools will enable real-time process and product quality monitoring and allow for future AI technology adoption.
- The facility has a ring corridor for suite access and a “science on display” viewing to showcase the facility to KBI clients.
KBI will use the facility as an option to provide clients with commercial launch material and market supply. KBI’s proven single-use platform ensures supply reliability with redundant equipment, automation, and full utility backup. Features include:
- Six 2,000-liter, single-use bioreactor systems and associated harvest and purification equipment can initially produce more than 70 batches per year and ramp up to meet additional demand.
- Advanced analytical services for commercial product characterization and release testing capabilities will support commercial launch and routine supply in tandem with the manufacturing operations.
“KBI prides itself on a creative approach to client collaboration,” said Landau. “Our customers turn to us to scale manufacturing processes suitable for commercial supply, and our scientific expertise with complex projects that deviate from standard planning protocol. It’s facilities like this and our strong client relationships that make this possible.”
This is the second major facility expansion announced by KBI within the last two years. KBI previously announced a new 5,600-square-meter biologic bulk drug substance manufacturing facility in Geneva, Switzerland. That facility is scheduled to be operational by mid-2022 and will employ more than 200 people in development, operations, and quality assurance positions.
About KBI Biopharma, Inc.
KBI Biopharma, a JSR Life Sciences company, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates into the clinic and beyond. KBI serves its global partners with multiple locations in Europe and the USA. www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005061/en/
Contact information
KBI Biopharma, Inc. Company Inquiries
Aruna Mor
KBI Biopharma, Inc.
amor@kbibiopharma.com
KBI Biopharma, Inc. Media Contact
Kristin Schaeffer
CG Life
kschaeffer@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KnowBe4 Appoints Bryan Palma as President and CEO29.4.2025 16:00:00 EEST | Press release
KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, announced that cybersecurity industry veteran Bryan Palma has been appointed president and chief executive officer of KnowBe4, effective May 5. KnowBe4’s founder and current chief executive officer Stu Sjouwerman has transitioned to the role of executive chairman. Palma is a highly regarded technology executive with over twenty-five years of experience and a proven track record of scaling global technology enterprises by driving profitable growth, improving customer experience, and delivering operational agility. Most recently, he was the chief executive officer of Trellix, a multi-billion dollar cybersecurity market leader formed through the merger of FireEye and McAfee Enterprise. Prior to joining Trellix, he guided some of the world’s leading organizations through pivotal technology and business transformations including Cisco, Boeing, EDS, PepsiCo, and the US Secret Service. Pal
Axel Springer Implements New Corporate Structure29.4.2025 15:36:00 EEST | Press release
Axel Springer SE ("Axel Springer") has implemented a new corporate structure as previously announced in September 2024. It has become effective by April, 29th 2025. The changes position all businesses for optimal future growth potential and success in their respective markets, strengthening Axel Springer as a transatlantic family-owned media company focused on digital journalism. The portfolio of successful media brands in Europe and the US includes, amongst others, BILD, BUSINESS INSIDER, MORNING BREW, POLITICO and WELT as well as, in the context of the joint venture operated together with Ringier Axel Springer in Poland, FAKT, FORBES, NEWSWEEK and ONET. It also comprises the marketing companies Bonial and Idealo, as well as Awin, and the digital research company Emarketer. KKR, through investment vehicles controlled by investment funds advised and managed by Kohlberg Kravis Roberts & Co. L.P. and its affiliates, and CPP Investments are divesting their shares in Axel Springer. Under t
C3ntro Telecom Unveils Tikva Project: A 2,500 km Fiber Network Connecting Mexico and the U.S.29.4.2025 15:35:00 EEST | Press release
C3ntro Telecom (C3ntro), a leader in global telecommunications and fiber infrastructure provider, announces today the launch of its most ambitious initiative to date: the Tikva Project. Tikva represents a transformative leap in cross-border connectivity, establishing a state-of-the-art, 2,500-kilometer fiber optic network between Phoenix, Arizona, and Querétaro, Mexico. Designed with AI-ready fiber technology, multi-duct capacity, and a diverse, low-latency Pacific route, Tikva delivers a fully underground, redundant cross-border solution. This milestone marks the first project of its kind in over 25 years and positions C3ntro as the single provider delivering unified service-level agreements (SLAs) across the U.S. and Mexico, while covering key cities along Mexico’s Pacific corridor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429510666/en/ The first of its kind in 25 years, this long haul fiber network will connect P
1NCE Raises $60 million USD in New Funding29.4.2025 15:15:00 EEST | Press release
1NCE, one of the fastest growing providers of IoT software and connectivity, today announced the completion of a $60 million USD funding round. 1NCE offers a software platform for connected products to more than 24,000 customers managing 30 million devices across 170+ countries. Since launching in the marketplace in 2018, the company has become an IoT industry disruptor by integrating connectivity as a component of its software platform. It currently operates the world’s largest IoT network in the cloud. 1NCE’s platform was recognized as the “Best Innovation in the Internet of Things” at the 2024 SaaS Awards. Since 2017, 1NCE has raised the equivalent of $160 million USD from investors from five countries. 1NCE’s list of investors to date now includes Deutsche Telekom, iSquared Capital, Kensington Capital Partners, SoftBank Corp., Vicenda Group, and Founder Alexander P. Sator. The funding round supports 1NCE’s plan to continue its global expansion, which started in 2022 with a focus on
Earnix, the Category Leader in Dynamic AI for the Insurance Industry, Acquires Zelros to Transform Insurers’ Business Performance29.4.2025 15:10:00 EEST | Press release
Earnix, the leading Dynamic AI platform for Insurance, today announced that it has signed a definitive agreement to acquire Zelros, a pioneer in Generative AI for insurers and banks. This innovative collaboration will bring the power of predictive, generative, and agentic AI across the entire risk decisioning, personalization, and claims cycle, thereby enabling pricing and underwriting professionals to deliver compelling offers while improving business performance. By combining Earnix’s advanced Predictive AI platform with Zelros’s GenAI recommendations engine, providers can now present the right offer, at the right price, at the right time. The joint offering provides precise decision-making at scale in regulated environments for pricing and product managers, underwriters, and agents, ultimately resulting in higher conversion rates with better customer engagement and satisfaction. Both companies bring demonstrated impact in supporting leading insurers and banks across the globe, inclu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom